Aronora is a privately held, early clinical stage translational biopharmaceutical company engaged in the discovery, research, and commercial development of proprietary biological therapeutics.
Aronora is committed to building a focused portfolio of safe drug products for a variety of clinical indications where there is significant unmet need. Aronora’s business strategy is to partner our innovative products during late preclinical to early proof-of-concept clinical stages.
To reach our objective, we have implemented a well-defined strategy that guides the identification of potential partnerships to support our product pipeline. We welcome qualified private investment, strategic partnerships, and out-licensing opportunities that are consistent with our business strategy.